Prevalence and outcome of comorbidities associated with acromegaly

PET-guided repeat transsphenoidal surgery for previously deemed unresectable lateral disease in acromegaly

(2020) Waiel A. Bashari et al.   Neurosurgical Focus

A Consensus on the Diagnosis and Treatment of Acromegaly Comorbidities: An Update

(2019) Andrea Giustina et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

10 Years' Experience of Using Low-Field Intraoperative MRI in Transsphenoidal Surgery for Pituitary Adenoma: Results of the Swiss Pituitary Registry (SwissPit)

(2019) Fabio Strange et al.   World Neurosurgery

The comprehensive impact on human body induced by resolution of growth hormone excess

(2018) Zhaoyun Zhang et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Persistence of Diabetes and Hypertension After Multimodal Treatment of Acromegaly

(2018) Baldomero González et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

A Consensus Statement on acromegaly therapeutic outcomes

(2018) Shlomo Melmed et al.   Nature Reviews Endocrinology

Changes in the management and comorbidities of acromegaly over three decades: the French Acromegaly Registry

(2017) Luigi Maione et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Somatostatin receptor ligands in the treatment of acromegaly

(2017) Monica R. Gadelha et al.   Pituitary

Endoscopic Transsphenoidal Approach for Acromegaly with Remission Rates in 401 Patients: 2010 Consensus Criteria

(2017) Ihsan Anik et al.   World Neurosurgery

Outcome of Endoscopic Transsphenoidal Surgery for Acromegaly

(2017) Jung Hee Kim et al.   World Neurosurgery

Complications of acromegaly: thyroid and colon

(2016) Amit Tirosh et al.   Pituitary

Epidemiology of acromegaly: review of population studies

(2016) Aikaterini Lavrentaki et al.   Pituitary

Challenges in the diagnosis and management of acromegaly: a focus on comorbidities

(2016) Alin Abreu et al.   Pituitary

Mortality in acromegaly: a 20-year follow-up study

(2015) Elina Ritvonen et al.   ENDOCRINE-RELATED CANCER

Percent reduction of growth hormone levels correlates closely with percent resected tumor volume in acromegaly

(2015) Lucia Schwyzer et al.   JOURNAL OF NEUROSURGERY

Relationship between parenchymal involvement and obstructive sleep apnea in subjects with sarcoidosis

(2014) Zuleyha Bingol et al.   Clinical Respiratory Journal

Surgical Interventions and Medical Treatments in Treatment-Naïve Patients With Acromegaly: Systematic Review and Meta-Analysis

(2014) Abd Moain Abu Dabrh et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Pasireotide Versus Octreotide in Acromegaly: A Head-to-Head Superiority Study

(2014) A. Colao et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

A consensus on the diagnosis and treatment of acromegaly complications

(2012) S. Melmed et al.   Pituitary

Pasireotide (SOM230) Demonstrates Efficacy and Safety in Patients with Acromegaly: A Randomized, Multicenter, Phase II Trial

(2010) S. Petersenn et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Effects of Initial Therapy for Five Years with Somatostatin Analogs for Acromegaly on Growth Hormone and Insulin-Like Growth Factor-I Levels, Tumor Shrinkage, and Cardiovascular Disease: A Prospective Study

(2009) Annamaria Colao et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Rapid and sustained reduction of serum growth hormone and insulin-like growth factor-1 in patients with acromegaly receiving lanreotide Autogel® therapy: a randomized, placebo-controlled, multicenter study with a 52 week open extension

(2009) Shlomo Melmed et al.   Pituitary

Acromégalie

(2008) Philippe Chanson   PRESSE MEDICALE

Risk of colorectal neoplasm in patients with acromegaly: A meta-analysis

(2008) Theodoros Rokkas et al.   WORLD JOURNAL OF GASTROENTEROLOGY